Clinical Trials
177
Active:11
Completed:43
Trial Phases
6 Phases
Early Phase 1:7
Phase 1:2
Phase 2:5
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
Not Applicable
92 (69.2%)Phase 4
21 (15.8%)Early Phase 1
7 (5.3%)Phase 3
6 (4.5%)Phase 2
5 (3.8%)Phase 1
2 (1.5%)Application of Pericapsular Nerve Group (PENG) Block
Not Applicable
Active, not recruiting
- Conditions
- TURBT
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Target Recruit Count
- 68
- Registration Number
- NCT07078773
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
Recruiting
- Conditions
- Neuroblastoma (NB)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-21
- Target Recruit Count
- 150
- Registration Number
- NCT07064746
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery
Not Applicable
Not yet recruiting
- Conditions
- Postoperative Delirium
- Interventions
- Drug: bupivacaine liposome (ultrasound-guided high iliofascial space block)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Target Recruit Count
- 40
- Registration Number
- NCT07066111
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
Not yet recruiting
- Conditions
- Ischemic Stroke
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Target Recruit Count
- 839
- Registration Number
- NCT07028775
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
Not Applicable
Not yet recruiting
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 410
- Registration Number
- NCT06987097
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next
News
No news found